iShares Biotechnology ETF
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
10% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 11 (+1) [Q4]
3% more first-time investments, than exits
New positions opened: 114 | Existing positions closed: 111
2% less funds holding
Funds holding: 880 [Q3] → 859 (-21) [Q4]
3.32% less ownership
Funds ownership: 66.12% [Q3] → 62.8% (-3.32%) [Q4]
11% less capital invested
Capital invested by funds: $5.15B [Q3] → $4.59B (-$566M) [Q4]
35% less repeat investments, than reductions
Existing positions increased: 207 | Existing positions reduced: 320
49% less call options, than puts
Call options by funds: $424M | Put options by funds: $829M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 10 articles about IBB published over the past 30 days
Neutral
See It Market
2 days ago
Key Stock Market ETFs, Bitcoin Creating A Story
This past week I wrote a lot about the relationship between silver, gold, bonds, the dollar and S&P 500. I also spoke in the media about those relationships as they are key right now to ascertain whether we are remaining in stagflation, heading towards recession, or resolving the uncertainty thereby seeing our way to growth.
Neutral
Zacks Investment Research
1 week ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Negative
Bloomberg Markets and Finance
2 weeks ago
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Negative
CNBC Television
2 weeks ago
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
Negative
CNBC
2 weeks ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Neutral
CNBC Television
3 weeks ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Reuters
3 weeks ago
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.
Negative
CNBC
3 weeks ago
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Negative
Market Watch
3 weeks ago
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Neutral
Zacks Investment Research
3 weeks ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Charts implemented using Lightweight Charts™